RxDoctor Payments Data

Tina Allenburg

Nurse Practitioner · Robbinsdale, MNNPI 1013028281

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Abbott at 46.9% of the total. Reporting peaked in 2024 at $1,465 and has fallen 90.6% since, to $137 in 2025. Among nurse practitioner clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,411in general payments, 2019–2025

Across 46 payments — averaging $74.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$1K
  • Medtronic$213
  • W. L. Gore & Associates, Inc.$128
  • Pfizer$83
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$54
  • plus $16 from 1 others

What the payments were for

  • Travel & lodging$1,56546%
  • Food & beverage$1,84654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,411 in reported general payments places this provider in the 95th percentile of 3,021 nurse practitioner providers in Minnesota.

See all nurse practitioner providers in Minnesota

Medicare billing

Part B allowed, 2024
$19,931
Medicare patients
164
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$177,387
EntrestoSacubitril/Valsartan84$91,063
Repatha SureclickEvolocumab43$58,887
XareltoRivaroxaban42$57,482
JardianceEmpagliflozin24$28,393
BrilintaTicagrelor17$22,259
Metoprolol Succinate447$9,670
Atorvastatin Calcium248$3,013
Losartan Potassium125$2,218
Isosorbide Mononitrate ErIsosorbide Mononitrate117$2,123
Lisinopril180$1,875
Rosuvastatin Calcium104$1,693
Torsemide57$1,625
Mexiletine Hcl12$1,551
ClopidogrelClopidogrel Bisulfate81$1,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$177,387133 claims
Johnson & JohnsonXarelto$16$57,48242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,021 nurse practitioner providers in Minnesota.

Other nurse practitioner in Robbinsdale

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →